{
  "uuid" : "",
  "id" : "hcc_easl_diagnostic.v0.0.1",
  "gdl_version" : "2.1",
  "concept" : "gt0001",
  "language" : {
    "original_language" : "ISO_639-1::en"
  },
  "description" : {
    "original_author" : {
      "name" : "Katja Mariko Wilde",
      "email" : "katja-wilde@t-online.de",
      "organisation" : "Cambio CDS",
      "date" : "2026-01-07"
    },
    "lifecycle_state" : "DRAFTED",
    "details" : {
      "en" : {
        "id" : "en",
        "purpose" : "To assess lesion size, interval ultrasound findings, and contrast-enhanced imaging characteristics in order to support diagnostic decision-making for suspected hepatocellular carcinoma.",
        "keywords" : [
          "hepatocellular",
          "carcinoma",
          "hcc",
          "diagnosis",
          "diagnostic assessment",
          "easl",
          "imaging"
        ],
        "use" : "Use to support diagnostic evaluation of suspected hepatocellular carcinoma in adult patients at increased risk of HCC.\n\nThe guideline evaluates lesion size, changes on follow-up ultrasound, and findings from contrast-enhanced four-phase CT or MRI, including the presence of arterial hyperenhancement with portal venous or delayed phase washout.\n\nBased on these inputs, the guideline determines whether imaging criteria for hepatocellular carcinoma are fulfilled or whether imaging evidence is insufficient for diagnosis, and provides recommendations for further diagnostic actions to enable diagnostic confirmation, such as repeat ultrasound, additional cross-sectional imaging, or multidisciplinary team assessment.",
        "misuse" : "Not to be used for diagnostic assessment of patients without increased risk of hepatocellular carcinoma.\n\nNot to be used for staging hepatocellular carcinoma according to BCLC, TNM, or other staging systems.",
        "copyright" : "© Cambio CDS"
      }
    },
    "other_details" : {
      "references" : "European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018 Jul;69(1):182-236. doi: 10.1016/j.jhep.2018.03.019. Epub 2018 Apr 5. Erratum in: J Hepatol. 2019 Apr;70(4):817. doi: 10.1016/j.jhep.2019.01.020. PMID: 29628281.\n\nRegionala cancercentrum i samverkan. Nationellt vårdprogram levercellscancer: Kapitel 8 Diagnostik och staging. Kunskapsbanken, 2024. Available at: https://kunskapsbanken.cancercentrum.se/diagnoser/levercellscancer/vardprogram/diagnostik/",
      "en" : "A structured diagnostic assessment used to evaluate whether hepatocellular carcinoma (HCC) can be diagnosed based on imaging findings and to recommend appropriate diagnostic actions in adult patients at increased risk of HCC, according to European Association for the Study of the Liver (EASL) diagnostic criteria."
    }
  },
  "definition" : { },
  "ontology" : {
    "term_definitions" : {
      "en" : {
        "id" : "en",
        "terms" : {
          "gt0001" : {
            "id" : "gt0001",
            "text" : "Hepatocellular carcinoma diagnostic assessment",
            "description" : "A structured diagnostic assessment used to evaluate whether hepatocellular carcinoma (HCC) can be diagnosed based on imaging findings and to recommend appropriate diagnostic actions in adult patients at increased risk of HCC, according to European Association for the Study of the Liver (EASL) diagnostic criteria."
          }
        }
      }
    }
  }
}